论文部分内容阅读
肺癌是发病率和死亡率增长最快 ,对人类健康和生命威胁最大的恶性肿瘤之一。其中非小细胞肺癌(ＮＳＣＬＣ)约占所有肺癌的 75%。随着化疗药物的发展 ,ＮＳＣＬＣ化疗的疗效不断提高[1～ 3] 。多西紫杉醇 (商品名为泰索帝 )为半合成的紫杉类药物 ,近年来国外大量报道多西紫杉醇
Lung cancer is one of the most rapidly growing malignant morbidity and mortality threats to human health and life. Among them, non-small cell lung cancer (NSCLC) accounts for about 75% of all lung cancers. With the development of chemotherapeutics, the efficacy of NSCLC chemotherapy has been continuously improved [1–3]. Docetaxel (trade name Taxotere) is a semi-synthetic taxane, and docetaxel has been widely reported abroad in recent years.